)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Karolinska Development
Karolinska Development (KDEV) investor relations material
Karolinska Development Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary28 Aug, 2026
Executive summary
Net loss for Q2 2026 was SEK -451.0 million, a significant increase from SEK -73.3 million in Q2 2025, mainly due to large downward revaluations of key portfolio holdings.
Net asset value (NAV) at June 30, 2026, was SEK 677.2 million, down from SEK 1,148.6 million a year earlier, with NAV per share at SEK 0.89 versus SEK 4.26.
Major strategic shift: acquisition of Rosetta's shares in KDev Investments, eliminating a complex structure and potential dividend obligations, improving transparency and direct exposure to portfolio value.
Portfolio companies advanced clinical programs, with several approaching key milestones in 2026–2027.
Financial highlights
Change in fair value of portfolio companies in Q2 2026 was SEK -446.8 million, driven by revaluations of Umecrine Cognition (down SEK 390.1 million) and Dilafor (down SEK 326.0 million).
Total portfolio fair value at June 30, 2026, was SEK 625.8 million, a decrease of SEK 693.6 million from the previous quarter.
Net sales for Q2 2026 were SEK 0.3 million (Q2 2025: SEK 0.4 million); for H1 2026, SEK 0.7 million (H1 2025: SEK 0.9 million).
Cash and cash equivalents at June 30, 2026, were SEK 51.4 million, down from SEK 71.1 million a year earlier.
Earnings per share for Q2 2026 were SEK -0.68 (Q2 2025: SEK -0.27).
Outlook and guidance
Several portfolio companies are expected to report Phase 2 and Phase 3 clinical data in 2026–2027, potentially enabling value-creating exits or licensing deals.
Umecrine Cognition and AnaCardio are approaching key clinical milestones, with data readouts expected in H2 2026.
Focus remains on advancing value-driving events and making underlying portfolio value more visible to shareholders.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Karolinska Development
- Q1 2026 saw a larger net loss, a successful rights issue, and key clinical progress in the portfolio.KDEV
Q1 2026 - Net loss widened in 2025, but a SEK 115m rights issue and clinical progress support future growth.KDEVQ4 2025
- Q3 2025 saw a sharp net loss and portfolio value drop, but clinical progress continued.KDEVQ3 2025
- Q2 2025 saw a sharp net loss and portfolio value drop, offset by improved liquidity from divestments.KDEVQ2 2025
- Portfolio value rose despite a net loss, with key clinical and investment milestones achieved.KDEVQ3 2024
- Q2 2024 saw a net loss, stable portfolio value, and major clinical and investment milestones.KDEVQ2 2024
- Q1 2025 saw a net loss and lower portfolio value, but strong clinical and financing milestones.KDEVQ1 2025
- 2024 saw a net loss but strong Q4 profit, major portfolio progress, and improved liquidity.KDEVQ4 2024
Next Karolinska Development earnings date
Q3 202613 Nov, 2026
Karolinska Development
Next Karolinska Development earnings date
Q3 202613 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Karolinska Development AB is a Sweden-based investment company that plays a significant role in the biotechnology sector. It is primarily engaged in providing capital, developing, and commercializing biotechnological products. The company's activities span a broad range of medical and therapeutic areas, including oncology, infections and wound healing, women’s health, cardiovascular and hematology, as well as medical equipment and diagnostics. Karolinska Development AB showcases a diverse portfolio that comprises investments in pharmaceutical research and development, healthcare technology, gene research and development, drug delivery technologies, and life sciences tools, among others. Founded in 2003 and with a modest team, the company focuses on fostering innovation and advancing the development of new treatments and medical solutions. The company is headquartered in Solna, Sweden, and its shares are listed on the Stockholm Stock Exchange.